David Kronn, MD
Clinical Genetics (M.D.) · Valhalla, NYNPI 1619979697
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 85.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $31,459 and has fallen 95.7% since, to $1,367 in 2025. Among clinical genetics (m.d.) clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $830.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$115K
- Spark Therapeutics, Inc.$6K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Amicus Therapeutics, Inc.$3K
- Sanofi-aventis U.S. LLC$3K
- Amgen$2K
- plus $2K from 11 others
Across 187 payments — averaging $13,782 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$2.4M
- Sanofi US Services Inc.$111K
- Biomarin Pharmaceutical Inc.$26K
- Amgen$21K
What the payments were for
- Consulting fees$58,69144%
- Speaking & faculty fees$58,65444%
- Travel & lodging$12,1259%
- Food & beverage$4,8324%
- Education$2880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 110 | $115,143 |
| Spark Therapeutics, Inc. | 7 | $5,937 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $4,320 |
| Amicus Therapeutics, Inc. | 5 | $2,806 |
| Sanofi-aventis U.S. LLC | 4 | $2,764 |
| Amgen | 1 | $2,100 |
| Cycle Pharmaceuticals Inc | 2 | $671 |
| Biomarin Pharmaceutical Inc. | 8 | $440 |
| Chiesi USA, Inc. | 1 | $104 |
| Ultragenyx Pharmaceutical Inc. | 3 | $90 |
| PTC Therapeutics, Inc. | 1 | $60 |
| Travere Therapeutics, Inc. | 7 | $42 |
| Shire North American Group Inc | 2 | $38 |
| CSL Behring | 1 | $23 |
| Mirum Pharmaceuticals, Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIZYME$30,974
- XENPOZYME$18,653
- NEXVIAZYME$14,551
- DISEASE STATE$6,222
- POMBILITI$2,530
- OPFOLDA$2,530
- ALDURAZYME$2,520
- RAVICTI$2,100
- NO PRODUCT DISCUSSED$669
- Nityr$600
- Palynziq$125
- FABRAZYME$108
- LAMZEDE$104
How this compares
$134,590 in reported general payments places this provider in the 95th percentile of 49 clinical genetics (m.d.) providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sapropterin Dihydrochloride | 78 | $792,970 |
| Potassium Chloride | 11 | $15,010 |
| CystagonCysteamine Bitartrate | 11 | $4,578 |
| LevocarnitineLevocarnitine (With Sugar) | 21 | $3,534 |
Paid to pharmacies, not to this prescriber.
Other clinical genetics (m.d.) in Valhalla
- Elizabeth Lim-MeliaValhalla$307
- Robert DesnickNew York$207K
- Manisha BalwaniNew York$188K
- Jaya GaneshNew York$65K
- Berrin MonteleoneMineola$50K
- George DiazNew York$44K
- Christopher CunniffNew York$25K
- David BeckNew York$21K
- Kimihiko OishiNew York$15K
- Mary LopiccoloNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.